NCT05223231 2026-02-02Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant TumorsNanjing Leads Biolabs Co.,LtdPhase 1/2 Completed26 enrolled